EA201892048A1 - Фармацевтическая композиция, содержащая эмпаглифлозин, и ее применения - Google Patents

Фармацевтическая композиция, содержащая эмпаглифлозин, и ее применения

Info

Publication number
EA201892048A1
EA201892048A1 EA201892048A EA201892048A EA201892048A1 EA 201892048 A1 EA201892048 A1 EA 201892048A1 EA 201892048 A EA201892048 A EA 201892048A EA 201892048 A EA201892048 A EA 201892048A EA 201892048 A1 EA201892048 A1 EA 201892048A1
Authority
EA
Eurasian Patent Office
Prior art keywords
emagagliflozin
applications
pharmaceutical composition
heart failure
preserved
Prior art date
Application number
EA201892048A
Other languages
English (en)
Inventor
Ули Брёдль
Афшин Сальсали
Ханс-Йюрген Вёрле
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Priority claimed from PCT/EP2017/055767 external-priority patent/WO2017157816A1/en
Publication of EA201892048A1 publication Critical patent/EA201892048A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к способам предотвращения или лечения острой или хронической сердечной недостаточности и снижения риска смерти по причине сердечно-сосудистой патологии, госпитализации в связи с сердечной недостаточностью и других состояний у пациентов с сохраненной или уменьшенной фракцией выброса путем введения эмпаглифлозина пациенту.
EA201892048A 2016-11-10 2017-03-13 Фармацевтическая композиция, содержащая эмпаглифлозин, и ее применения EA201892048A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662420062P 2016-11-10 2016-11-10
PCT/EP2017/055767 WO2017157816A1 (en) 2016-03-16 2017-03-13 Pharmaceutical composition comprising empagliflozin and uses thereof

Publications (1)

Publication Number Publication Date
EA201892048A1 true EA201892048A1 (ru) 2019-04-30

Family

ID=66436974

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892048A EA201892048A1 (ru) 2016-11-10 2017-03-13 Фармацевтическая композиция, содержащая эмпаглифлозин, и ее применения

Country Status (1)

Country Link
EA (1) EA201892048A1 (ru)

Similar Documents

Publication Publication Date Title
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
PH12020500555A1 (en) Esketamine for the treatment of depression
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
EA201500997A1 (ru) Терапевтические применения эмпаглифлозина
AU2014375637A1 (en) Formula of neuregulin preparation
BR112015017251A8 (pt) composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
BR112017020307A2 (pt) método para inibir os sintomas associados com a ingestão de álcool, e, composição farmacêutica
CO2017001899A2 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañía
BR112018074299A2 (pt) composições farmacêuticas compreendendo eteplirsen
MD4763C1 (ru) Фармацевтическая композиция
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
EA201892048A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин, и ее применения
BR112017015840A2 (pt) método de tratamento ou prevenção de eventos aterotrombóticos em pacientes com histórico de infarto do miocárdio
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
EA202090028A1 (ru) Способы уменьшения или предотвращения сердечно-сосудистых явлений у пациентов с сахарным диабетом ii типа
EA201991119A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
SG10201903656RA (en) Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor
GR1008769B (el) Οξινο διαλυμα αιμοκαθαρσης με l-ασκορβικο οξυ (βιταμινη c)